EUVIMEDEUVIMED entdecken
Crossref

Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies

Maria G Tektonidou, Katerina Laskari, Demosthenes B Panagiotakos, Haralampos M Moutsopoulos

Arthritis Care & Research · 15.01.2009 · 61 (1) · 29-36

DOI: 10.1002/art.24232 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis Care & Research, online erschienen am 30.12.2008. Verfasst von Maria G Tektonidou und 3 weiteren Autor:innen. Beteiligte Einrichtung: National University of Athens, Athens, Greece. balts@otenet.gr. Die Arbeit wurde bisher 333-mal zitiert (Crossref) und nennt 51 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Antiphospholipid antibodies (aPL), namely anticardiolipin antibodies (aCL) and lupus anticoagulant (LAC), have been associated with an increased risk of thrombosis in systemic lupus erythematosus (SLE). We examined additional thrombosis risk factors (aPL profile, SLE‐related, and traditional risk factors) and the primary thrombosis prevention in SLE patients with and without aPL.

Methods

All SLE patients with positive aPL but without previous thrombotic manifestations who were regularly followed up at our department (n = 144) and 144 age‐ and sex‐matched SLE patients with negative aPL were included in this study. The median followup times were 104 and 112 months, respectively. The demographic, clinical, laboratory, and treatment characteristics and the traditional thrombosis risk factors were recorded.

Results

The thrombosis rate was 29 per 144 aPL‐positive patients (20.1%) and 11 per 144 aPL‐negative patients (7.6%; P = 0.003). In multiadjusted analysis, significant predictors of thrombosis were male sex (hazard ratio [HR] 6.25, P < 0.01), LAC (HR 3.48, P = 0.04), and constantly positive aCL (HR 5.87, P = 0.01) for aPL‐positive patients, while male sex (HR 7.14, P = 0.03) and hypertension were predictors for aPL‐negative patients (HR 6.49, P = 0.03). Additionally, the duration of low‐dose aspirin treatment played a protective role against thrombosis in aPL‐positive patients (HR per month 0.98, P = 0.05), as did the duration of hydroxychloroquine in both aPL‐positive (HR per month 0.99, P = 0.05) and aPL‐negative patients (HR per month 0.98, P = 0.04).

Conclusion

Independent predictors of thrombosis for aPL‐positive patients were male sex, LAC, and constantly positive aCL, and for aPL‐negative patients were male sex and hypertension. The duration of low‐dose aspirin use played a protective role against thrombosis in aPL‐positive patients as did the duration of hydroxychloroquine in both groups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdolescentAdultAnti-Inflammatory Agents, Non-SteroidalAntibodies, AntiphospholipidAntirheumatic AgentsAspirinFemaleFollow-Up StudiesHumansHydroxychloroquineLupus Coagulation InhibitorLupus Erythematosus, SystemicMaleMultivariate AnalysisRisk FactorsSex CharacteristicsThrombosisYoung Adult

Substanzen

Anti-Inflammatory Agents, Non-SteroidalAntibodies, AntiphospholipidAntirheumatic AgentsLupus Coagulation InhibitorHydroxychloroquineAspirin

Autor:innen und Institutionen

  • National University of Athens, Athens, Greece. balts@otenet.gr

Zitieren

APA

Tektonidou, M. G., Laskari, K., Panagiotakos, D. B., & Moutsopoulos, H. M. (2009). Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Care & Research, 61(1), 29-36. https://doi.org/10.1002/art.24232

Vancouver

Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Care & Research. 2009;61(1):29-36. doi:10.1002/art.24232

BibTeX
@article{Tektonidou2009,
  author = {Tektonidou, Maria G and Laskari, Katerina and Panagiotakos, Demosthenes B and Moutsopoulos, Haralampos M},
  title = {Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies},
  journal = {Arthritis Care & Research},
  year = {2009},
  volume = {61},
  number = {1},
  pages = {29--36},
  doi = {10.1002/art.24232}
}
Kostenlos starten →